Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Fremanezumab reduces migraine days

Elaine Soliven
16 Aug 2019

Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduces the number of migraine days in patients with chronic migraine (CM) or episodic migraine (EM), according to the FOCUS* study presented at AHS 2019.

This phase III, international, double-blind, parallel-group trial evaluated 838 adults diagnosed with CM or EM (aged ≤50 years) with previous inadequate responses to 2–4 classes of preventive treatments. Participants were randomized in a 1:1:1 ratio to receive subcutaneous injections of fremanezumab, either monthly** (n=283) or quarterly*** (n=276), or monthly placebo (n=278) for 12 weeks. [AHS 2019, abstract IOR08]

At baseline, the mean number of migraine days was 14.1 days for those assigned to monthly or quarterly fremanezumab and 14.3 days for those in the placebo group.

Significantly more patients treated with monthly or quarterly fremanezumab achieved a ≥50 percent reduction in monthly average number of migraine days compared with placebo at 4 weeks (36 and 38 percent, respectively, vs 10 percent; p<0.0001) and within 12 weeks after the first dose (34 percent in each group vs 9 percent; p<0.0001).

More fremanezumab recipients also experienced a reduction of ≥75 percent in monthly average number of migraine days than the placebo recipients at 4 weeks (14 percent for both the monthly and quarterly dose vs 2 percent; p<0.0001) and within 12 weeks after the first dose (12 percent vs 2 percent; p<0.0001 for the monthly dose and 8 percent vs 2 percent; p<0.005 for the quarterly dose).

A greater proportion of patients on monthly and quarterly fremanezumab sustained ≥50 percent reduction in the monthly average number of migraine days between the first 4 and 12 weeks of treatment (19 percent for monthly and 20 percent for quarterly vs 3 percent; p<0.0001) compared with placebo.

“[This] … study of fremanezumab was the first and largest study of a migraine preventive treatment in adults with both CM and EM,” said investigator Dr Egilius Spierings from MedVadis Research in Boston, Massachusetts, US, who presented the study.

“Monthly or quarterly fremanezumab treatment resulted in clinically meaningful and statistically significant reductions in migraine days … [among] patients with EM or CM ... Given the multiple previous preventive treatment failures in these patients, response rates reported here suggest [that] fremanezumab offers an effective treatment opportunity in this potentially more difficult-to-treat migraine population,” Spierings noted.

 

*FOCUS: An efficacy and safety study of fremanezumab in adults with migraine

**Monthly dosage: CM (month 1: 675 mg, months 2–3: 225 mg); EM (months 1–3: 225 mg)

***Quarterly dosage: CM or EM (month 1: 675 mg, months 2–3: placebo)

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
3 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.